跳至主要内容
临床试验/NCT00479687
NCT00479687已完成不适用

A Multi-center, Randomized, Double-blind, Placebo Controlled Trial of SUPARTZ (Sodium Hyaluronate) for the Treatment of Chronic Shoulder Pain

Bioventus LLC0 个研究点目标入组 300 人开始时间: 2007年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Bioventus LLC
入组人数
300
主要终点
Visual Analogue Scale (VAS: 0-100) for Pain on Movement

研究概览

简要总结

This clinical trial is to determine the safety and effectiveness of three injections of SUPARTZ (sodium hyaluronate) compared with phosphate buffered saline (PBS) for the treatment of glenohumeral osteoarthritis of the shoulder. The trial contains two phases. Phase I is 26 weeks, double blinded, and subjects are randomized to either SUPARTZ or PBS treatment. Phase II is 26 weeks (total 52 weeks) and open-label so all subjects will receive SUPARTZ injections only.

详细描述

Phase 3 Study: Multi-center, randomized, double blinded, two phase study to determine the safety and efficacy of 3 injections of SUPARTZ for Osteoarthritis of the Shoulder

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
35 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Glenohumeral Osteoarthritis (OA) confirmed by radiograph
  • Limitation of shoulder motion in at least one direction
  • Retained active range of motion of at least 30% in all directions

排除标准

  • Full thickness rotator cuff tear or rotator cuff tendinopathy
  • Frozen shoulder
  • Female who is pregnant or lactating

结局指标

主要结局

Visual Analogue Scale (VAS: 0-100) for Pain on Movement

时间窗: Ph1: weeks 7 - 26

Visual Analogue Scale (VAS) for pain on (shoulder) movement with a range of 0 to100; where 0=No pain at all and 100=Pain as bad as it can be. Q: How bad is the pain in your study shoulder with activity or movement? (For example, when putting on a coat, sleeping on your study shoulder side, combing your hair, reaching a high shelf, etc.) Reported is a single Least square mean point estimate over the 7-26 week time interval using the assessments collected at weeks 7, 13, 20, and 26

次要结局

未报告次要终点

研究者

发起方
Bioventus LLC
申办方类型
Industry
责任方
Sponsor

相似试验